Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association

Benjamin, Emelia J.; Muntner, Paul; Alonso, Álvaro; Bittencourt, Márcio Sommer; Callaway, Clifton W.; Carson, April P.; Chamberlain, Alanna M.; Chang, Alexander R.; Cheng, Susan; Das, Sandeep R; Delling, Francesca N.; Djoussé, Luc; Elkind, Mitchell S.V.; Ferguson, Jane F.; Fornage, Myriam; Jordan, Lori Chaffin; Khan, Sadiya S.; Kissela, Brett M; Knutson, Kristen L.; Kwan, Tak; Lackland, Daniel T.; Lewis, Tené T.; Lichtman, Judith H.; Longenecker, Chris T.; Loop, Matthew Shane; Lutsey, Pamela L.; Martin, Seth S.; Matsushita, Kunihiro; Moran, Andrew E.; Mussolino, Michael E.; O’Flaherty, Martin; Pandey, Ambarish; Perak, Amanda M.; Rosamond, Wayne D.; Roth, Gregory A.; Sampson, Uchechukwu K.A.; Satou, Gary; Schroeder, Emily B.; Shah, Svati H.; Spartano, Nicole L.; Stokes, Andrew; Tirschwell, David; Tsao, Connie W.; Turakhia, Mintu P.; VanWagner, Lisa B.; Wilkins, John T.; Wong, Sally S.; Virani, Salim S.

doi:10.1161/cir.0000000000000659

Cited by 6,503 publications

(3,910 citation statements)

References 2,487 publications

Supporting

Mentioning

3,749

Contrasting

Unclassified

Order By: Relevance

“…Deep vein thrombosis (DVT) involves the development of a blood clot localized within the great veins of the body, commonly in the lower extremities . In the presence of May‐Thurner syndrome (MTS), also known as iliac vein compression syndrome or Cockett's syndrome, patients are predisposed to an iliofemoral thrombosis due to an anatomical variant in which the right common iliac artery overlies and compresses the left common iliac vein against the lumbar spine .…”

Section: Overview Of May‐thurner Syndome (Mts) Pathophysiology and CLmentioning

confidence: 99%

May‐Thurner syndrome: History of understanding and need for defining population prevalence

Harbin

Lutsey

2020

Journal of Thrombosis and Haemostasis

Self Cite

View full text Add to dashboard Cite

Patients with May‐Thurner syndrome (MTS) are at elevated risk of developing an extensive left iliofemoral deep vein thrombosis (DVT; localized blood clot) due to an anatomical variant where the right common iliac artery compresses the left common iliac vein against the lumbar spine. While MTS was initially presumed to be rare when it was first anatomically defined in 1957, case reports of this syndrome have recently become more frequent, perhaps due to improved imaging techniques allowing for enhanced visualization of the iliac veins. Still, the population burden of this condition is unknown, and there is speculation it may be higher than generally perceived. In the present review, we (a) review history of how MTS became recognized, (b) describe practical challenges of studying MTS in population‐based settings due to the specialized imaging required for diagnosis, (c) discuss why the contribution of MTS to DVT may be underestimated, (d) describe uncertainty regarding the degree of venous compression which leads to DVT, and (e) outline future research needs. Our goal is to raise awareness of MTS and spark additional research into the epidemiology of this condition, which may be an underappreciated causative venous thromboembolism risk factor.

show abstract

Section: Overview Of May‐thurner Syndome (Mts) Pathophysiology and CLmentioning

confidence: 99%

May‐Thurner syndrome: History of understanding and need for defining population prevalence

Harbin

Lutsey

2020

Journal of Thrombosis and Haemostasis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Impaired wound healing in diabetic patients, especially of the foot, can have dire consequences through infection and necrosis. Together with their high prevalence in western‐style societies, cardiovascular ischemic diseases pose a heavy social and economic burden, due to early mortality, impaired quality of life with pain and loss of mobility, and recurrent hospitalization . Current treatments for CAD and PAD mainly include endovascular procedures such as balloon angioplasty/stenting and bypass surgery or possibly exercise training for limb ischemia.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic vascularization in regenerative medicine

Gianni‐Barrera

Maggio

Melly

et al. 2020

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Therapeutic angiogenesis, that is, the generation of new vessels by delivery of specific factors, is required both for rapid vascularization of tissue‐engineered constructs and to treat ischemic conditions. Vascular endothelial growth factor (VEGF) is the master regulator of angiogenesis. However, uncontrolled expression can lead to aberrant vascular growth and vascular tumors (angiomas). Major challenges to fully exploit VEGF potency for therapy include the need to precisely control in vivo distribution of growth factor dose and duration of expression. In fact, the therapeutic window of VEGF delivery depends on its amount in the microenvironment around each producing cell rather than on the total dose, since VEGF remains tightly bound to extracellular matrix (ECM). On the other hand, short‐term expression of less than about 4 weeks leads to unstable vessels, which promptly regress following cessation of the angiogenic stimulus. Here, we will briefly overview some key aspects of the biology of VEGF and angiogenesis and discuss their therapeutic implications with a particular focus on approaches using gene therapy, genetically modified progenitors, and ECM engineering with recombinant factors. Lastly, we will present recent insights into the mechanisms that regulate vessel stabilization and the switch between normal and aberrant vascular growth after VEGF delivery, to identify novel molecular targets that may improve both safety and efficacy of therapeutic angiogenesis.

show abstract

“…Heart failure (HF) is a progressive process and remains a major global burden in terms of morbidity and mortality . Despite advances in pharmacological and resynchronization device therapy, many patients worsen to end‐stage HF.…”

mentioning

confidence: 99%